Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis

Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis

Recombinant-modified vaccinia virus Ankara (rMVA) is known to elicit potent antitumor immune responses in preclinical models due to its inherent ability to activate the innate immune system and the activation of adaptive responses mediated by the expression of tumor antigens and costimulus-providing...

Full description

Bibliographic Details
Main Authors: Ángela Bella, Leire Arrizabalaga, Claudia Augusta Di Trani, Assunta Cirella, Myriam Fernandez-Sendin, Celia Gomar, Joan Salvador Russo-Cabrera, Inmaculada Rodríguez, José González-Gomariz, Maite Alvarez, Álvaro Teijeira, José Medina-Echeverz, Maria Hinterberger, Hubertus Hochrein, Ignacio Melero, Pedro Berraondo, Fernando Aranda
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
Peritoneal carcinomatosis
CD40L
CD137L
CD8 immune response
cancer immunotherapy
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2098657

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2022.2098657

Similar Items